Olfera is developing a biopharmaceutical platform that utilizes the olfactory system as a direct delivery pathway to the brain, enabling the effective administration of existing neurological drugs while bypassing the blood-brain barrier. This approach addresses the low bioavailability of therapeutic proteins and antibodies in treating neurological disorders, offering a non-invasive alternative for patients with conditions such as epilepsy and dementia.
Funding
$200K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Neurological disorders affect a significant portion of the global population, yet effective drug delivery to the brain remains a challenge due to the blood-brain barrier. Traditional methods often result in low bioavailability of therapeutic proteins and antibodies at the target site, limiting treatment efficacy. This is particularly problematic for conditions like epilepsy and dementia, where timely intervention is crucial.
Solution
Olfera is developing a biopharmaceutical platform that leverages the olfactory system to bypass the blood-brain barrier and directly deliver neurological drugs to the brain. This innovative approach enhances the bioavailability of both existing FDA-approved and novel therapeutic proteins and antibodies. By utilizing the olfactory pathway, Olfera aims to create fast-acting drugs that can halt epilepsy within seconds and optimize medications for convenient nasal spray administration for dementia patients. The platform facilitates drug discovery, optimization, and effective delivery through advanced screening technology and pioneering chemistry, transforming challenging oral side effects into more manageable treatments. Olfera's technology is designed to be compatible with all major drug modalities, offering a non-invasive alternative for patients.
Target Audience
Olfera's primary target audience includes patients suffering from neurological conditions such as epilepsy and dementia, as well as pharmaceutical companies seeking innovative drug delivery methods.
Features
- Utilizes the olfactory system as a direct drug-delivery pathway to the brain, bypassing the blood-brain barrier.
- Employs advanced screening technology for drug discovery and optimization.
- Transforms existing FDA-approved neurological drugs into more effective treatments.
- Enables fast-acting drugs that can reach the brain within seconds.
- Optimizes medications for nasal spray administration.
- Compatible with all major drug modalities.